Importantly, TP53 alterations found in cancer, as in the case of CLL, not only may abolish the transactivating activity of the protein toward target genes, but, in many cases, may promote the onset of new deleterious functions, defined as Gain of Functions, which may strongly affect cancer progression and the response to therapy. This evidence concerns the gene TP53 and cancer.